Clinical Trials Browser

Unknown × OTHER × durvalumab × Clear all

NCT04159974 2024-05-09

RICE

Phase 2 Unknown

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT06255262 2024-02-13

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Phase 1/2 Unknown

Gastrointestinal

Biliary Tract Neoplasms

NCT05092412 2024-01-12

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

Phase 2 Unknown

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03691714 2023-12-08

Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Unknown

Head and Neck Neoplasms, Neoplasm Metastasis

NCT04985851 2023-12-01

To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.

Phase NA Unknown

Small Cell Lung Carcinoma

NCT05935579 2023-11-15

Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Phase 2 Unknown

Gastrointestinal

Biliary Tract Neoplasms

NCT05451173 2023-10-03

Combining ICI With SBRT or HypoFrx-RT for ES NSCLC

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04364776 2023-09-28

Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.

Lung Neoplasms

NCT05128630 2023-09-28

DEDALUS

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04083365 2023-05-31

PANDORA

Phase 2 Unknown

Gastrointestinal

Rectal Neoplasms

NCT05382741 2023-05-17

VIVA

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04202809 2023-05-10

ESPADURVA

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03994393 2023-04-21

ILLUMINATE

Phase 2 Unknown

EGFR Mutant Advanced Non Small Cell Lung Cancer

NCT04646837 2023-03-29

Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03975114 2023-03-24

MILES-5

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04543110 2023-03-23

RADIANT

Phase 2 Unknown

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03737968 2023-03-21

Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

Phase 2 Unknown

Laryngeal Diseases

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT04359199 2023-02-10

QUASAR

Squamous Cell Carcinoma of Head and Neck, Deglutition Disorders, Head and Neck Neoplasms, Oropharyngeal Neoplasms

NCT05312216 2023-01-26

Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT05672537 2023-01-05

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

Phase 2 Unknown

Gastrointestinal

Cholangiocarcinoma

NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Phase 2 Unknown

Gastrointestinal

Resectable Biliary Tract Cancer

NCT04015739 2022-08-17

BOLD

Phase 2 Unknown

Carcinoma, Ovarian Epithelial, Recurrence

NCT03780608 2022-06-15

This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)

Phase 2 Unknown

Melanoma

NCT05327582 2022-04-14

An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC

Phase 1/2 Unknown

Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms

NCT03799744 2022-03-28

Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma

Phase 1 Unknown

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT03759496 2022-03-23

Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer

Phase 2 Unknown

Urinary Bladder Neoplasms, Neoplasms

NCT05267392 2022-03-04

IDEAR

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05245994 2022-02-18

An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese

Phase 2 Unknown

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05157542 2021-12-15

Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05034133 2021-09-05

Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer

Phase 2 Unknown

Limited Stage Small Cell Lung Cancer

NCT05008861 2021-08-17

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03450967 2021-08-10

Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck

NCT04982549 2021-08-06

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Phase 2 Unknown

Unresectable Stage III NSCLC

NCT04961918 2021-07-14

The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT04293419 2021-06-21

DUREC

Phase 2 Unknown

Gastrointestinal

Rectal Neoplasms

NCT04913480 2021-06-04

SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT04517227 2021-05-03

The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)

Phase NA Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT03699449 2021-04-01

An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

Phase 2 Unknown

Platinum-resistant Recurrent Ovarian Cancer

NCT03951415 2021-04-01

DOMEC

Phase 2 Unknown

Uterine Neoplasms, Endometrial Neoplasms

NCT03824691 2021-02-25

ARCADIA

Phase 2 Unknown

Urinary Bladder Neoplasms

NCT03377400 2020-12-17

Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

Phase 2 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04672759 2020-12-17

A Real-world Study of Durvalumab for Lung Cancer in China

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT04621370 2020-11-09

PRIME-RT

Phase 2 Unknown

Gastrointestinal

Rectal Neoplasms

NCT04613284 2020-11-03

RELIEF

Phase 4 Unknown

Lung Neoplasms

NCT04443322 2020-09-22

Dulect2020-1

Phase NA Unknown

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04447612 2020-06-25

Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 2 Unknown

Nasopharyngeal Carcinoma

NCT04444193 2020-06-23

Dulect2020-2

Phase NA Unknown

Endometrial Neoplasms

NCT04314297 2020-03-19

Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

Phase 2 Unknown

Small Cell Lung Carcinoma